Key facts
- Manuals
- 1
- Languages
- ZH
- Last added
- 2023-11-15
Featured Xi'an-Janssen manuals

Xi'an-Janssen Ibrutinib Capsules 140 mg Package Insert
This is the Chinese package insert for Ibrutinib Capsules (商品名称 亿珂®/IMBRUVICA®), a 140 mg hard gelatin capsule from Xi'an-Janssen. It states that the capsules, taken orally once daily, are indicated as monotherapy for patients with mantle cell lymphoma (MCL) and for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior therapy.
The insert details the recommended doses (560 mg once daily for MCL; 420 mg once daily for CLL/SLL), dose adjustments for toxicity, co-administration with CYP3A inhibitors, use in hepatic impairment, missed doses, and special populations such as women and men of childbearing potential. It then presents adverse reaction data from clinical trials including PCYC-1104-CA, MCL-3001, PCYC-1102-CA, PCYC-1112-CA, PCYC-1115-CA and CLL-3001. This manual is written in Chinese.
Covers: Drug Name · Ingredients · Description · Indications · Specification · Dosage and Administration
Latest Xi'an-Janssen manuals
Xi'an-Janssen Ibrutinib Capsules 140 mg Package Insert
Other 31 pages · 1 MB · ZHChinese package insert for Xi'an-Janssen Ibrutinib Capsules (IMBRUVICA, 140 mg) covering indications, dosage, and adverse reactions for MCL and CLL/SLL.
Questions answered in Xi'an-Janssen manuals
What is Ibrutinib Capsules indicated for?
It is used as monotherapy for patients with mantle cell lymphoma who have received at least one prior therapy, and for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one prior therapy.
From: Xi'an-Janssen Ibrutinib Capsules 140 mg Package Insert
How should Ibrutinib Capsules be taken?
The capsules are given orally once daily, swallowed whole with water at roughly the same time each day; do not open, break or chew the capsule.
From: Xi'an-Janssen Ibrutinib Capsules 140 mg Package Insert
